← Retour au Screener

Sector: Santé
Open in Terminal → CRVSLive chart · Key metrics · News · Smart money

Corvus Pharmaceuticals

CRVS Small Cap

Healthcare · Biotechnology

Mis à jour: Aug 2, 2026, 22:14 UTC

11,52 €
+0.53% aujourd'hui
52W: 3,52 € – 23,42 €
52W Low: 3,52 € Position: 40.2% 52W High: 23,42 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
969 M €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-30.46%
Rentabilité des capitaux propres
Beta
0.82
Sensibilité au marché
Positions vendeuses
24.42%
% du flottant vendu à découvert
Volume moyen
1,446,967
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Achat Fort
7 analysts
Avg. Price Target
28,80 €
+149.95% upside
Target Range
23,46 € – 36,50 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 37 Exchange: NGM

Corvus Pharmaceuticals en bref

Corvus Pharmaceuticals (CRVS) is currently trading at 11,52 € with a market capitalization of 969 M €. The 52-week range spans from 3,52 € to 23,42 €; the current price is 50.8% below the yearly high.

💰 Dividende

Corvus Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Corvus Pharmaceuticals (CRVS) au consensus : Achat Fort. L'objectif de cours moyen est de 28,80 €, soit un potentiel de +149.95% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 23,46 € à 36,50 €.

Corvus Pharmaceuticals : la thèse d'investissement en détail

Corvus Pharmaceuticals (CRVS) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 149.95% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 24.42% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 149.95% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Strong Buy
  • Bilan solide avec faible endettement (D/E 0.35)
Points faibles
  • Positions vendeuses élevées (24.42%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
11,52 €
+0% vs. cours
MM 200 jours
11,26 €
+2.31% vs. cours
Sous le plus haut 52s
−50.8%
23,42 €
Au-dessus du plus bas 52s
+227.4%
3,52 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
0.82 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
24.42% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.35 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (24.42%).

Trading Data

50-Day MA: 11,52 €
200-Day MA: 11,26 €
Volume: 775,851
Avg. Volume: 1,446,967
Short Ratio: 12.38
P/B Ratio: 4.63x
Debt/Equity: 0.35x
Free Cash Flow: -19 616 532 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Corvus Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut